Snippets from EASD 2023

Abstracts of the 59th EASD Annual Meeting,2-6 October 2023. Diabetologia 2023,66(Suppl1): S1–S536. https://doi.org/10.1007/s00125-023-05969-6 (downloadable pdf)

Franks PW, Cefalu WT, Dennis J, et al. Precision Medicine 1. Precision medicine for cardiometabolic disease: a framework for clinical translation. Lancet Diabetes Endocrinol October 2023. https://doi.org/10.1016/S2213-8587(23)00165-1

Misra S, Aquilar-Salina CA, Chikowore T, et al. Precision Medicine 2. The case for precision medicine in the prevention, diagnosis, and treatment of cardio- metabolic diseases in low-income and middle-income countries. Lancet Diabetes Endocrinol October 2023. https://doi.org/10.1016/S2213-8587(23)00164-X

Leslie RD, Ma RCW, Franks PW, et al. Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes. Lancet Diabetes Endocrinol October 2023. https://doi.org/10.1016/S2213-8587(23)00159-6

Szczerbinski L, Florez JC. Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future. Precision medicine 4. Lancet Diabetes Endocrinol October 2023. https://doi.org/10.1016/S2213-8587(23)00232-2

Shehadeh N, Barrett T, Galassetti P, et al. Dapagliflozin or saxagliptin in pediatric type 2 diabetes. A phase 2 randomized trial New Engl J Med Evidence https://doi.org/10.1056/EVIDoa2300210

ABCD worldwide audit of testosterone deficiency in men with type 2 diabetes http://www.diabetologists-abcd.org.uk/Testosterone/Testosterone_Deficiency_Diabetes_Nationwide_Audit.htm

Krogvold L, Mynarek IM, Ponzi E, et al. Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial. Nature Med October 2023. https:// doi.org/10.1038/s41591-023-02576-1

Incretins in metabolic disease: pathophysiology and therapy. Special Issue. Diabetologia; 66: pp107.